NTLA – Intellia Therapeutics, Inc.
NTLA — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
34.29
Margin Of Safety %
Put/Call OI Ratio
0.31
EPS Next Q Diff
-1.65
EPS Last/This Y
0.68
EPS This/Next Y
1.41
Price
11.94
Target Price
25.88
Analyst Recom
2.26
Performance Q
-12.91
Upside
-1,084.9%
Beta
1.8
Ticker: NTLA
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | NTLA | 13.02 | 0.29 | 0.54 | 93716 |
| 2026-07-14 | NTLA | 13.29 | 0.31 | 0.24 | 96231 |
| 2026-07-15 | NTLA | 13.03 | 0.31 | 0.65 | 97241 |
| 2026-07-16 | NTLA | 11.85 | 0.30 | 1.56 | 96778 |
| 2026-07-17 | NTLA | 11.38 | 0.28 | 0.93 | 97153 |
| 2026-07-20 | NTLA | 10.91 | 0.28 | 0.33 | 67992 |
| 2026-07-21 | NTLA | 11.47 | 0.28 | 0.08 | 70249 |
| 2026-07-22 | NTLA | 11.14 | 0.28 | 0.29 | 70685 |
| 2026-07-23 | NTLA | 11.1 | 0.28 | 0.48 | 71098 |
| 2026-07-24 | NTLA | 10.74 | 0.28 | 0.34 | 72139 |
| 2026-07-27 | NTLA | 10.68 | 0.28 | 1.07 | 72313 |
| 2026-07-28 | NTLA | 10.94 | 0.30 | 0.89 | 74005 |
| 2026-07-29 | NTLA | 10.81 | 0.31 | 0.24 | 75401 |
| 2026-07-30 | NTLA | 11.13 | 0.31 | 0.29 | 75688 |
| 2026-07-31 | NTLA | 10.68 | 0.31 | 0.04 | 75958 |
| 2026-08-03 | NTLA | 10.76 | 0.31 | 0.24 | 76403 |
| 2026-08-04 | NTLA | 11.3 | 0.30 | 0.35 | 77069 |
| 2026-08-05 | NTLA | 10.96 | 0.31 | 0.97 | 78506 |
| 2026-08-06 | NTLA | 11.25 | 0.32 | 0.60 | 79997 |
| 2026-08-07 | NTLA | 11.95 | 0.31 | 0.35 | 79877 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | NTLA | 13.02 | 19.6 | 14.0 | -3.14 |
| 2026-07-14 | NTLA | 13.31 | 19.6 | -42.7 | -3.14 |
| 2026-07-15 | NTLA | 13.04 | 19.6 | -20.2 | -3.14 |
| 2026-07-16 | NTLA | 11.85 | 19.6 | 18.6 | -3.14 |
| 2026-07-17 | NTLA | 11.38 | 19.6 | -8.6 | -3.14 |
| 2026-07-20 | NTLA | 10.91 | 19.6 | -8.1 | -3.14 |
| 2026-07-21 | NTLA | 11.47 | 19.6 | -59.4 | -3.14 |
| 2026-07-22 | NTLA | 11.15 | 19.6 | -15.5 | -3.14 |
| 2026-07-23 | NTLA | 11.10 | 19.6 | -29.3 | -3.14 |
| 2026-07-24 | NTLA | 10.73 | 19.6 | -11.8 | -3.14 |
| 2026-07-27 | NTLA | 10.68 | 19.6 | -28.1 | -3.14 |
| 2026-07-28 | NTLA | 10.88 | 19.6 | -41.3 | -3.14 |
| 2026-07-29 | NTLA | 10.82 | 19.6 | -27.0 | -3.14 |
| 2026-07-30 | NTLA | 11.11 | 19.6 | -46.3 | -3.14 |
| 2026-07-31 | NTLA | 10.66 | 19.6 | -9.2 | -3.14 |
| 2026-08-03 | NTLA | 10.76 | 19.6 | -35.0 | -3.14 |
| 2026-08-04 | NTLA | 10.76 | 19.6 | -35.0 | -3.14 |
| 2026-08-05 | NTLA | 10.95 | 19.6 | -13.4 | -3.14 |
| 2026-08-06 | NTLA | 11.24 | 19.6 | -45.5 | -3.14 |
| 2026-08-07 | NTLA | 11.94 | 19.9 | -64.6 | -3.13 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | NTLA | -0.15 | 4.27 | 36.86 |
| 2026-07-14 | NTLA | -0.15 | 4.27 | 36.87 |
| 2026-07-15 | NTLA | -0.15 | 4.27 | 36.87 |
| 2026-07-16 | NTLA | -0.15 | 4.27 | 36.87 |
| 2026-07-17 | NTLA | -0.15 | 4.27 | 36.87 |
| 2026-07-20 | NTLA | -0.15 | 4.03 | 36.87 |
| 2026-07-21 | NTLA | -0.15 | 4.03 | 36.87 |
| 2026-07-22 | NTLA | -0.15 | 4.03 | 36.87 |
| 2026-07-23 | NTLA | -0.15 | 4.03 | 36.87 |
| 2026-07-24 | NTLA | -0.15 | 4.03 | 36.87 |
| 2026-07-27 | NTLA | -0.28 | 3.88 | 34.29 |
| 2026-07-28 | NTLA | -0.28 | 3.88 | 34.29 |
| 2026-07-29 | NTLA | -0.28 | 3.88 | 34.29 |
| 2026-07-30 | NTLA | -0.28 | 3.88 | 34.29 |
| 2026-07-31 | NTLA | -0.28 | 3.88 | 34.29 |
| 2026-08-03 | NTLA | -0.28 | 3.78 | 34.29 |
| 2026-08-04 | NTLA | -0.28 | 3.78 | 34.29 |
| 2026-08-05 | NTLA | -0.28 | 3.78 | 34.29 |
| 2026-08-06 | NTLA | -0.28 | 3.78 | 34.29 |
| 2026-08-07 | NTLA | -0.28 | 3.78 | 34.29 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.87
Avg. EPS Est. Current Quarter
-0.78
Avg. EPS Est. Next Quarter
-0.78
Insider Transactions
-0.28
Institutional Transactions
3.78
Beta
1.8
Average Sales Estimate Current Quarter
13
Average Sales Estimate Next Quarter
13
Fair Value
Quality Score
17
Growth Score
46
Sentiment Score
71
Actual DrawDown %
93.4
Max Drawdown 5-Year %
-96.4
Target Price
25.88
P/E
Forward P/E
PEG
P/S
28.03
P/B
2.3
P/Free Cash Flow
EPS
-3.36
Average EPS Est. Cur. Y
-3.13
EPS Next Y. (Est.)
-1.73
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-672.16
Relative Volume
0.87
Return on Equity vs Sector %
-90.9
Return on Equity vs Industry %
-74.8
EPS 1 7Days Diff
EPS 1 30Days Diff
0.04
EBIT Estimation
-64.6
◆
NTLA
Healthcare
$11.94
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
47.6
Range 1M
24.7%
Sup Dist
9.5%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
15.9%
EPS NY
41%
52W%
19.4%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+116.8% upside
Upside
+116.8%
Quality
17
NTLA — P/E HistoricalBiotechnology
Intellia Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 377
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
NTLA
Latest News
—
Caricamento notizie per NTLA…
stock quote shares NTLA – Intellia Therapeutics, Inc. Stock Price stock today
news today NTLA – Intellia Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch NTLA – Intellia Therapeutics, Inc. yahoo finance google finance
stock history NTLA – Intellia Therapeutics, Inc. invest stock market
stock prices NTLA premarket after hours
ticker NTLA fair value insiders trading